ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

Expected Findings of the SWOG S1505 Trial in Pancreatic Cancer

Davendra Sohal, MD, MPH
Published Online:3:08 PM, Fri October 27, 2017

Davendra Sohal, MD, MPH, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the SWOG S1505 trial, which is exploring perioperative mFOLFIRINOX versus gemcitabine and nab-paclitaxel (Abraxane) in patients with resectable pancreatic adenocarcinoma.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.